PATENT CLAIM ANALYSIS

Application Number: 15915554
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["435", "007920"]

Abstract:
Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.

Claim (Index 20):
The method of  claim 13 , the sample being taken from a subject, further comprising determining or diagnosing the presence of a PMD in the subject according to one or more of:\n the presence of the soluble, misfolded protein in the sample compared to a control sample taken from a control subject; an amount of the soluble, misfolded protein in the sample compared to a predetermined threshold amount, the detecting comprising detecting the amount of the soluble, misfolded protein in the sample; the presence of the soluble, misfolded protein in the sample, the subject exhibiting no clinical signs of dementia according to cognitive testing; as a contributing factor to one or more clinical signs of dementia in the subject according to the presence of the soluble, misfolded protein in the sample, the subject exhibiting the one or more clinical signs of dementia according to cognitive testing; the presence of the soluble, misfolded protein in the sample, the subject exhibiting no clinical signs of dementia according to cognitive testing; and a progression or homeostasis of a PMD in the subject by comparing the amount of the soluble, misfolded protein in the sample to an amount of the soluble, misfolded protein in a comparison sample taken from the subject at a different time compared to the sample.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 90.0
- Lexical Diversity: 2.24675
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14852471', '12177012', '13833008', '15424444', '14330445']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5970400092959223
- 35 USC 102 Novelty (BERT): 0.6144523534912156
- Combined Prediction Score: 0.5987812437154517
- Mean Citation Score: 334.639886
- Max Citation Score: 699.6428
- Similarity Product: 479.7604972183466

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test